North America & Europe Age-related Macular Degeneration Therapeutics Market

North America & Europe Age-related Macular Degeneration Therapeutics Market, By Disease Type, By Drug Type, By Distribution Channel, By Region (North America and Europe)-Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Age-related macular degeneration (AMD) is an eye disease that can blur central vision. It happens when aging causes damage to the macula the part of the eye that controls sharp, straight-ahead vision. The macula is part of the retina (the light-sensitive tissue at the back of the eye). AMD is a common condition and a leading cause of vision loss in older adults. AMD doesn’t cause complete blindness, but losing central vision can make it harder to complete even daily activities. AMD happens very slowly in some people and faster in others. The detection of AMD also takes long time. There are 2 types of AMD: dry and wet. Most people with AMD have dry AMD (also called atrophic AMD). This is when the macula gets thinner with age. Dry AMD happens in 3 stages: early, intermediate, and late. It usually progresses slowly over several years. There’s no treatment for late dry AMD, but there are ways to make the most of the remaining vision. And if only one eye has late dry AMD then proper treatment can protect the other eye. Wet AMD (also called advanced neovascular AMD), is a less common type of late AMD that usually causes faster vision loss. Any stage of dry AMD can turn into wet AMD. It happens when abnormal blood vessels grow in the back of the eye and damage the macula. Treatment options are available for wet AMD. Early dry AMD doesn’t cause any symptoms. In intermediate dry AMD, some people still have no symptoms. Others may notice mild symptoms, like mild blurriness in their central vision or trouble seeing in low lighting. In late AMD (wet or dry type), many people notice that straight lines start to look wavy or crooked. A blurry area near the center of vision can also be seen. Over time, this blurry area may get bigger, or blank spots may appear. Colors may also seem less bright than before, and cause more trouble seeing in low lighting.

Market Dynamics

Increasing launches of new products, and mergers and acquisitions by key market players is expected to drive the North America & Europe age-related macular degeneration therapeutics market growth. For instance, on February 7, 2022, U.S. Food and Drug Administration had approved a new drug Vabysmo (faricimab-svoa) for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME), two of the leading causes of vision loss. It’s the first injectable eye medication that has been approved for the treatment of both conditions and offers a more flexible dosing regimen than medications currently used. Vabysmo is the first bi-specific antibody approved for the eye.

Key features of the study:

• This report provides an in-depth analysis of the North America & Europe age-related macular degeneration therapeutics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the North America & Europe age-related macular degeneration therapeutics market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Novartis AG, Bayer AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Pfizer, Inc., Valeant Pharmaceuticals International, Inc., AbbVie Inc., Viatris Inc., and Amgen Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• North America & Europe age-related macular degeneration therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the North America & Europe age-related macular degeneration therapeutics market

Detailed Segmentation:

• North America & Europe Age-related Macular Degeneration Therapeutics Market, By Disease Type:
• Dry AMD
• Wet AMD
• North America & Europe Age-related Macular Degeneration Therapeutics Market, By Drug Type:
• Aflibercept (Eylea)
• Ranibizumab (Lucentis)
• Bevacizumab (Avastin)
• Pegaptanib (Macugen)
• Verteporfin (Visudyne)
• Brolucizumab (Beovu)
• Supplements
• Others
• North America & Europe Age-related Macular Degeneration Therapeutics Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• North America & Europe Age-related Macular Degeneration Therapeutics Market, By Region:
• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Company Profiles
• Novartis AG
• Bayer AG
• Bausch Health Companies Inc.
• Regeneron Pharmaceuticals, Inc.
• Hoffmann-La Roche AG
• Pfizer, Inc.
• Valeant Pharmaceuticals International, Inc.
• AbbVie Inc.
• Viatris Inc.
• Amgen Inc.